Telix Pharmaceuticals Limited (NASDAQ:TLX) Short Interest Up 82.7% in July

Telix Pharmaceuticals Limited (NASDAQ:TLX) was the target of a large increase in short interest in July. As of July 15th, there was short interest totaling 297,140 shares, an increase of 82.7% from the June 30th total of 162,625 shares. Based on an average trading volume of 165,030 shares, the short-interest ratio is currently 1.8 days. Approximately 0.1% of the shares of the stock are short sold.

Telix Pharmaceuticals Trading Down 1.3%

Shares of Telix Pharmaceuticals stock opened at $9.97 on Thursday. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $14.27. The company has a 50-day simple moving average of $10.33 and a 200 day simple moving average of $9.23. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.

Wall Street Analyst Weigh In

TLX has been the subject of several recent research reports. Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Friday, July 17th. Citigroup lowered their price objective on Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Tuesday, July 7th. Finally, Royal Bank Of Canada downgraded Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.40.

Institutional Trading of Telix Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Rhumbline Advisers raised its stake in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares during the last quarter. Bank of America Corp DE grew its position in Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the last quarter. XTX Topco Ltd acquired a new stake in Telix Pharmaceuticals during the 4th quarter valued at $89,000. XY Capital Ltd acquired a new stake in Telix Pharmaceuticals during the 1st quarter valued at $120,000. Finally, IHT Wealth Management LLC bought a new position in Telix Pharmaceuticals in the 2nd quarter valued at $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.